Press Release

Ability Pharma sponsors the 37th National Meeting of the Spanish Society of Pharmacology

March 3, 2017

Barcelona (Catalonia, Spain), March 7, 2017. Ability Pharmaceuticals, a drug development biopharmaceutical company specialized in oncology, announced the sponsorship of the of 37th National Meeting of the Spanish Society of Pharmacology (SEF). The Meeting will be held in Barcelona from Sunday 18th to Wednesday 21th June 2017, with the British Pharmacological Society (BPS) as the main guest (http://www.sef2017.com).
 
This meeting will display the world class research carried out not only by SEF and BPS members but also by researchers worldwide whose investigation revolves around the pharmacology field. The programme combines plenary lectures, symposia, oral presentations and posters, to stimulate the scientific discussion as well as to set new collaborations and research opportunities especially for young researchers.
 
Dr. José Alfón, the VP of research and developmend of Ability Pharma, will be opening the Session 14 (Pharmacology of Anti-Cancer Drugs) on Wednesday 21th June, presenting our main project ABTL0812, an autophagy-anticancer drug in Phase II clinical trials.

LATEST NEWS

11.05.2021

Press Release

Ability Pharmaceuticals Announces the Inclusion of the First Patients in a Phase 2b Clinical Trial with ABTL0812 + FOLFIRINOX as First Line Therapy in Advanced Pancreatic Cancer simultaneously in USA and Europe + info
28.12.2020

Press Release

The Chinese pharmaceutical company SciClone joins the capital of AbilityPharma with an investment commitment of three million dollars + info
16.12.2020

Press Release

The antitumoral drug ABTL0812 shows promising results against neuroblastoma + info
05.11.2020

Press Release

AbilityPharma receives the approval from the FDA and the AEMPS to start the clinical trial of its molecule against pancreatic cancer in the US and Spain + info
22.10.2020

Press Release

AbilityPharma receives a 1.6 million euro grant from the FDA and opens a crowdfunding campaign in Capital Cell + info
22.09.2020

Press Release

ABILITYPHARMA PRESENTS THE RESULTS OF A NEW FIRST-LINE TREATMENT FOR ENDOMETRIAL CANCER + info
09.06.2020

Press Release

AbilityPharma publishes full characterization of mechanism of action of ABTL0812, a Phase II clinical inducer of cytotoxic autophagy in cancer cells, in Autophagy journal + info
25.03.2020

Press Release

AbilityPharma awarded €5 million from the Horizon Europe EIC Accelerator Pilot Program to conduct a Phase 2b clinical trial with ABTL0812 in patients with advanced pancreatic cancer + info
12.09.2019

Press Release

AbilityPharma rises € 3.5 million in a financing round to complete the current oncologic phase 2 clinical trial and license ABTL0812 to an international pharmaceutical company + info
© 2012 Ability Pharma / All Rights Reserved / Legal Notice / Privacy Police
NEORG